|
FY2024
12 months to Dec 31, 2024
|
FY2023
12 months to Dec 31, 2023
|
FY2022
12 months to Dec 31, 2022
|
FY2021
12 months to Dec 31, 2021
|
FY2020
12 months to Dec 31, 2020
|
|
|---|---|---|---|---|---|
| Cash flows from operating activities: | |||||
| Net income | |||||
| Adjustments to reconcile net income to net cash provided by operating activities: | |||||
| Provision for credit losses | |||||
| Depreciation and amortization | |||||
| Stock-based compensation expense | |||||
| Income on bank-owned life insurance, net | |||||
| Net losses on sales of debt securities | |||||
| Net (gains) losses on equity securities | |||||
| Mortgage loans originated for sale | |||||
| Proceeds from mortgage loans sold | |||||
| Net gains on sales of loans | |||||
| Net gains on sales of OREO | |||||
| Loss on termination of swaps | |||||
| Changes in: | |||||
| Net decrease (increase) in other assets | |||||
| Net (decrease) increase in other liabilities | |||||
| Net cash provided by operating activities | |||||
| Cash flows from investing activities: | |||||
| Proceeds from sales of debt securities | |||||
| Purchase of debt securities | |||||
| Proceeds from maturities, calls and pay-downs of debt securities | |||||
| Net purchases of equity securities | |||||
| Net purchases of FHLB capital stock | |||||
| Net increase in loans | |||||
| Additions to premises and equipment, net | |||||
| Proceeds from OREO sales | |||||
| Purchase of bank-owned life insurance | |||||
| Net cash used in investing activities | |||||
| Cash flows from financing activities: | |||||
| Net increase (decrease) in deposits | |||||
| Net (decrease) increase in borrowed funds | |||||
| Net increase in short-term borrowings | |||||
| Advancements from long-term borrowings | |||||
| Repayments of long-term borrowings | |||||
| Repayment of subordinated debt | |||||
| Loss on extinguishment of subordinated debt | |||||
| Proceeds from the issuance of subordinated debt | |||||
| Cash dividends paid, net of dividend reinvestment plan | |||||
| Proceeds from issuance of common stock | |||||
| Net settlement for employee taxes on restricted stock and options | |||||
| Net proceeds from stock option exercises | |||||
| Net cash provided by (used in) financing activities | |||||
| Net increase (decrease) in cash and cash equivalents | |||||
| Cash and cash equivalents at beginning of year | |||||
| Cash and cash equivalents at end of year | |||||
Loading...